Risperidone-induced Marked Elevation of Serum Creatine Kinase in Adolescence

Abstract

We report on a 17-year-old boy who developed a marked increase in serum creatine kinase (CK) (9743 U/l) during treatment with risperidone for catatonic psychosis. Known causes of elevated CK such as delirium, malignant neuroleptic syndrome, infection, cocaine overdose, trauma, and intramuscular injections were ruled out. Vital signs remained always within the normal range. On discontinuation of risperidone, serum CK concentrations returned to 105 U/l within 1 week and remained within normal limits. While a transient moderate increase in CK activity at admission may be related to acute psychosis, risperidone seems to be the causative agent for the later marked elevation. To our knowledge, this is the first reported case of risperidone-associated elevation of serum CK in an adolescent. While discontinuation of risperidone does not seem necessary in patients with a moderate increase of serum CK, withdrawal of neuroleptics is warranted in more severe cases.

References

• 1 Blumensohn R, Yoran-Hegesh R, Golubchik P, Mester R, Fluhr H, Hermesh H, Weizman A. Elevated serum creatine kinase activity in adolescent psychiatric inpatients on admission.  Int Clin Psychopharmacol. 1998;  13(6) 269-272
• 2 Bottlender R, Jager M, Hofschuster E, Dobmeier P, Moller H J. Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient.  Pharmacopsychiatry. 2002;  35 119-121
• 3 Hermesh H, Manor I, Shiloh R, Weizman R, Munitz H. Absence of myoglobinuria in acute psychotic patients with marked elevation in serum creatine phosphokinase level.  Eur Neuropsychopharmacol. 2001;  11(2) 111-115
• 4 Hesslinger B, Walden J, Normann C. Acute and long-term treatment of catatonia with risperidone.  Pharmacopsychiatry. 2001;  34 25-26
• 5 Kohnke M D, Griese E U, Stosser D, Gaertner I, Barth G. Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone.  Pharmacopsychiatry. 2002;  35 116-118
• 6 Kruger E, Lohse H. Serum-Kreatinphosphiokinase bei endogener Psychose [Serum creatinphosphokinase (CPK) in endogenic psychoses].  Psychiatr Neurol Med Psychol (Leipz). 1975;  27(3) 140-146 (Germany)
• 7 Manor I, Hermesh H, Valevski A, Benjamin Y, Munitz H, Weizman A. Recurrence pattern of serum creatine phosphokinase levels in repeated acute psychosis.  Biol Psychiat. 1998;  43(4) 288-292
• 8 Marcus E L, Vass A, Zislin J. Marked elevation of serum creatine kinase associated with olanzapine therapy.  Ann Pharmacother. 1999;  33(6) 697-700
• 9 Meltzer H Y, Cola P A, Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment.  Neuropsychopharmacology. 1996;  15(4) 395-405
• 10 Reznik I, Volchek L, Mester R, Kotler M, Sarova-Pinhas I, Spivak B, Weizman A. Myotoxicity and neurotoxicity during clozapine treatment.  Clin Neuropharmacol. 2000;  23(5) 276-280
• 11 Rosebraugh C J, Flockhart D A, Yasuda S U, Woosley R L. Olanzapine-induced rhabdomyolysis.  Ann Pharmacother. 2001;  35(9) 1020-1023